dual Bcl-2/Bcl-xL inhibitors (Infinity/Novartis)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug Namedual Bcl-2/Bcl-xL inhibitors (Infinity/Novartis)
Drug Alias Namedual Bcl-2/Bcl-xL inhibitors (Infinity)IPI-565IPI-983L
ClassificationSmall molecules
Mechanisms of ActionApoptosis stimulantsApoptosis regulator Bcl-X inhibitors
TargetsApoptosis regulator Bcl-X
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSwitzerland
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesInfinity Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNovartis AgInfinity Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A